42 results about "Secondary hypoparathyroidism" patented technology

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor PTHR1, also known as parathyroid hormone / parathyroid hormone related protein receptor. The PTHR1 compounds are derived from the intracellular loops and domains of the PTHR1 receptor. The invention also relates to the use of these PTHR1 receptor compounds and pharmaceutical compositions comprising the PTHR1 receptor compounds in the treatment of diseases and conditions associated with PTHR1 receptor modulation, such as osteoporosis; humoral hypercalcemia of malignancy; osteolytic and osteoblastic metastasis to bone; primary and secondary hyperparathyroidism associated increase in bone absorption; vascular calcification; psychiatric disorders and cognitive disorders associated with hyperparathyroidism; dermatological disorders; and excess hair growth.

The present invention relates to novel methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism. One determines and monitors the level of parathyroid hormone agonist and parathyroid hormone antagonist in the renal patient. The parathyroid hormone suppressing therapeutic is administered to the patient so as to minimize the level of parathyroid hormone antagonist.

A method of treating and preventing secondary hyperparathyroidism in CKD by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin Din a patient by administering 25-hydroxyvitamin D3 with or without 25-hydroxyvitamin D2 and, as necessary, 1,25-dihydroxyvitamin D2 as a Vitamin D hormone replacement therapy.

The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or lanthanum hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The capsules of the present invention dissolve at a similar rate before and after storage. The oral pharmaceutical capsules of the present invention can be administered to treat a patient at risk for or suffering from hyperphosphatemia, at risk for or suffering from chronic kidney disease (CKD), at risk for or suffering from soft tissue calcification associated with CKD, or at risk for or suffering from secondary hyperparathyroidism.

The invention belongs to the field of medicinal chemistry, and particularly relates to a novel crystalline form A of doxercalciferol and a preparation method for the novel crystalline form A. The invention further comprises a pharmaceutical composition of the novel crystalline form A of doxercalciferol and an application of the composition for treating osteoporosis or secondary hyperparathyroidism. By virtue of Cu-Kalpha radiation, X-ray powder diffraction has diffraction peaks at positions where 2theta angles are 7.82, 8.51, 12.06, 13.01, 15.60, 17.05, 17.82, 18.71, 19.35, 20.06, 20.37, 20.62, 21.98, 22.68, 22.90, 23.81 and 24.79. The invention further discloses a technically improved scheme for preparing high purity doxercalciferol at the same time. The scheme is simple in step, easy to operate, short in consumed time and low in cost, and industrial large-scaled production is quite facilitated.

Methods for treating subjects suffering from chronic kidney disease-mineral and bone disorder or other disorders resulting in primary or secondary hyperparathyroidism are described. The methods are effective in reducing serum parathyroid hormone (PTH) levels and calcium levels in patients who undergo hemodialysis. The methods described herein are also effective in slowing the progression of kidney disease and preserving kidney function. Compositions used in the described methods are also provided and comprise calcimimetics which function as agonists of the calcium sensing receptor (CaSR).

A computer-implemented method for determining at least one secondary hyperparathyroidism risk factor (“SHPT”) for a patient is implemented using a risk evaluation computer system in communication with a memory. The method includes receiving a plurality of demographic data associated with a patient from a mobile computing device, receiving a concentration of a renal filtration marker associated with the patient from the mobile computing device, and determining at least one SHPT risk factor for the patient based on the plurality of demographic data and the concentration of the renal filtration marker using at least one estimating equation, the SHPT risk factor indicating a likelihood that the patient has SHPT.

The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and / or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and / or treatment.

The invention relates to novel medicinal application of medical carbon, in particular to the application of the medicinal carbon in the preparation of medicaments for curing hyperphosphatemia. In the invention, clinical tests prove that the medicinal carbon, when taken orally, can reduce the serium inorganic phosphorus level and the product of calcium and phosphorus of patients who have received hemodialysis and peritoneal dialysis but do not have the hyperphosphatemia controlled after receiving the treatment by the calcium-containing phosphate binder, and provides a voltage detection (VD) therapy opportunity for patients with secondary hyperparathyroidism which cannot be treated by the VD therapy because of over-high product of calcium and phosphorus. The medical carbon is favorable for reducing and preventing angiocardiopathy development death, caused by chronic kidney disease-mineral and bone disorder (CKD-MBD), of the dialysis patients. Thus, the medicinal carbon can be used as novel medicaments for curing the hyperphosphatemia of patients with dialysis.

19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 3β-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, metabolic bone diseases, osteomalacia, osteopenia, secondary hyperparathyroidism, psoriasis, or other skin diseases.

The invention relates to the technical field of calcitriol, in particular to an oral solution containing calcitriol and a preparation method of the oral solution, and the oral solution containing calcitriol comprises the following components in parts by weight: 0.290-0.305 part of calcitriol; 29.7 to 30.3 parts of butyl hydroxy anisole; 29.8 to 30.2 parts of butylated hydroxytoluene (BHM); and 299987 to 300012 parts of medium chain triglycerides. The preparation method of the oral solution containing calcitriol comprises the following steps: S100, weighing: turning on a yellow light lamp in a weighing room, weighing calcitriol, medium chain triglyceride, butylated hydroxyanisole and butylated hydroxytoluene according to parts by weight, and carrying out double-person rechecking; compared with the prior art, the oral solution containing calcitriol has the following beneficial effects that the oral solution containing calcitriol can make up the blank in the field of treating secondary hyperparathyroidism of patients with moderate to severe chronic renal failure before dialysis and follow-up metabolic bone diseases and hypoparathyroidism in domestic children medication, and the clinical requirements are met.

The invention provides for methods of using 20-methyl Gemini vitamin D3 compounds to treat osteoporosis and secondary hyperparathyroidism.

19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 3β-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, metabolic bone diseases, osteomalacia, osteopenia, secondary hyperparathyroidism, psoriasis, or other skin diseases.

Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25 -hydroxy vitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient' s serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxy vitamin D.

Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 to treat and / or prevent secondary hyperparathyroidism and / or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.

The invention discloses a method for preparing paricalcitol. Nandrolone is taken as a raw material, oxidation, Wittig reaction, hydroxyl protection, bromination, rearrangement, hydrogen bromide removal, addition, oxidation, reduction, hydroxyl deprotection and ring opening are carried out, so that the paricalcitol is obtained. The paricalcitol is used for preventing and treating secondary hyperparathyroidism.

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia and / or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and / or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25 -hydroxy vitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient' s serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25 -hydroxy vitamin D.

The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or lanthanum hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The capsules of the present invention dissolve at a similar rate before and after storage. The oral pharmaceutical capsules of the present invention can be administered to treat a patient at risk for or suffering from hyperphosphatemia, at risk for or suffering from chronic kidney disease (CKD), at risk for or suffering from soft tissue calcification associated with CKD, or at risk for or suffering from secondary hyperparathyroidism.

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, suchas cinacalcet or a pharmaceutically acceptable salt thereof, and / or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and / or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

The invention belongs to the field of medicinal chemistry, and in particular relates to a new crystal form A of docalciferol and a preparation method thereof. The invention also relates to a pharmaceutical composition containing the new crystal form A of docalciferol and its role in the treatment of osteoporosis Hyperparathyroidism or secondary hyperparathyroidism. The new crystal form A of docalciferol, using Cu-Kα radiation, X-ray powder diffraction at 2θ angles at 7.82, 8.51, 12.06, 13.01, 15.60, 17.05, 17.82, 18.71, 19.35, 20.06, There are diffraction peaks at 20.37, 20.62, 21.98, 22.68, 22.90, 23.81, and 24.79. At the same time, the invention also discloses a process improvement scheme for preparing high-purity doxercalciferol, which has simple steps, easy operation, short time consumption and low cost, and is very beneficial to large-scale industrial production.

The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.

Methods for treating vitamin D insufficiency and secondary hyperparathyroidism in patients having CKD comprising administering repeat doses of 25-hydroxyvitamin D are disclosed. The methods comprise administering 25-hydroxyvitamin D in an amount effective to safely raise the patient's serum 25-hydroxyvitamin D level to greater than 90 ng / ml and / or to control the patient's serum ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D to less than 20.

The invention relates to a rhythmic photostimulation pattern system and application thereof. In the rhythmic photostimulation pattern system, a cycle of photostimulation is four weeks, the frequency of photostimulation is three times per week, and the time of photostimulation at a time is 10 to 40 minutes. The rhythmic photostimulation pattern system disclosed by the invention can be used for effectively improving osteoporosis induced by secondary hyperparathyroidism, remarkably inhibiting excessive secretion of parathyroid hormones induced by the secondary hyperparathyroidism, remarkably reversing bone density and / or bone bulk density decrease induced by the secondary hyperparathyroidism, activating differentiating and aging of osteoblasts and inhibiting differentiating and aging of osteoclasts, and thus, osteogenesis can be greater than osteoclastogenesis. The rhythmic photostimulation pattern system is very convenient in operating mode, and an entire process is free of introductionof drug for intervention, so that a side effect resulting from employing the system is lower compared with that of drug therapy, and the safety is higher.

The invention discloses a fully humanized monoclonal single-domain antibody for resisting human PTH1R and an application of the fully humanized monoclonal single-domain antibody. The amino acid sequence of the antibody is shown as SEQ ID NO: 2. According to the invention, aiming at wild and mutant human PTH1R ECD proteins, antibody screening is carried out by using a phage display technology, and the anti-human PTH1R blocking type single-domain antibody with a blocking effect is screened and obtained through methods such as ELISA, FACS and the like. The antibody can be combined with human PTH1R, can block the interaction between PTH and PTH1R, and has a potential application value in human body dysfunction mediated by PTH-PTH1R, such as chronic kidney disease secondary hyperparathyroidism.